Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. ACN
5. IBM
6. META
7. SPY
8. NVDA
9. PRIM
10. PFE

Go back to Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn

Beyond Air, Inc. (XAIR) Reports In-Line Q1 EPS, Revenues Beat

November 11, 2020 4:32 PM EST

Beyond Air, Inc. (NASDAQ: XAIR) reported Q1 EPS of ($0.30), in-line with the analyst estimate of ($0.30). Revenue for the quarter came in at $349.6 thousand versus the consensus estimate of $120 thousand.

Over the past few months we have achieved several significant milestones, both regulatory and clinical, across our development pipeline. Most notably, we filed a PMA for the LungFit PH system for the treatment of PPHN, which will be subject to the standard 180-day FDA... More